focus -WSS

focus

author：focus 2025-09-29 21:14:07 - browse：62

Business standing in the middle of a maze near a bag with a dollar sign on it. -- biotech coverage from STAT — Adobe

Over the last year or two, something curious has started occurring in the conference rooms and private Zoom meetings of biotech venture capitalists.

Representatives from pension funds, college endowments, family offices, and other organizations with money to invest have become bolder in their requests, according to interviews with a host of VCs. They’re pushing not only for advantageous terms in a VC firm’s latest fund, but in some cases, have angled for equity in the firm itself. These types of conditions aren’t unheard of, but have become more frequent as venture capitalists have a harder time raising funds, and as outside investors feel empowered to ask for more bang for their buck.

“A lot is changing in venture fundraising right now,” said Nan Li, co-founder and managing partner of Dimension, which launched last January. Outside investors tried to ask for a piece of Dimension, but the new firm had more than enough interest in its first fund and was able to turn down those proposals. Two other young VC firms told STAT they’ve fielded similar requests, and one investment group reported that it had managed to negotiate an equity stake in a VC firm.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： RaDonda Vaught to speak at CommonSpirit event on patient safety

leisure time

WSS

Some top drug companies are starting to take action on climate

ALS groups 'won't be played again' by the FDA, drug sponsors

Flu vaccine offering decent levels of protection this winter, new data show

CRISPR base editing slashes cholesterol levels in monkeys

Some top drug companies are starting to take action on climate

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

entertainment

focus

hotspot

Walensky prepares to leave CDC — and Congress — behind

In search for therapies for solid tumors, companies turn to claudin

Apple is now the first public company to be valued at $3 trillion

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

Bright Health sells Medicare Advantage business to Molina

Health insurers' Q3 question: how much care are people getting?

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

2023 Nobel Prize in Medicine goes to Karikó and Weissman

Wikipedia

What will Novo Nordisk's VC do with its influx of cash?

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

In search for therapies for solid tumors, companies turn to claudin

Flu, Covid vaccination rates decline, new survey data show

2023 Nobel Prize in Medicine goes to Karikó and Weissman

Some top drug companies are starting to take action on climate

hotspot

focus

leisure time

leisure time